Hormone Research • 2026 Guide

Testosterone Replacement Therapy:
The Complete Research Guide

Testosterone replacement therapy (TRT) is the medical treatment for hypogonadism, used by over 2.5 million American men to restore testosterone levels from below 300 ng/dL to an optimal 700–1000 ng/dL range. This guide covers every TRT protocol — cypionate, enanthate, cream, and pellets — with clinical trial data, side effect management, and bloodwork monitoring schedules.

Last Updated: March 18, 2026  ·  MeetPeptide Research Team
0%
of men over 45 have clinically low testosterone
300→800
ng/dL average testosterone increase on TRT
0M
US men currently on testosterone therapy

Overview

What Is Testosterone Replacement Therapy?

Testosterone replacement therapy (TRT) is a medical treatment for hypogonadism — a condition where the testes produce insufficient testosterone. It restores serum testosterone to normal physiological levels (400–800 ng/dL) through exogenous testosterone delivery via injection, topical, or implant methods.
TRT is medically indicated when a patient has two morning testosterone measurements below 300 ng/dL combined with symptoms of hypogonadism. Symptoms include fatigue, reduced libido, erectile dysfunction, loss of lean muscle mass, increased body fat, depressed mood, and impaired concentration. Approximately 4–5 million US men have hypogonadism, yet the majority remain undiagnosed or untreated.
⚠️
Diagnosis requires two tests. A single low testosterone reading is insufficient. Two fasting, morning blood draws (before 10am) on separate days are required per Endocrine Society and AUA guidelines before starting TRT.
🎯

Medical Indication

Total testosterone <300 ng/dL on two morning tests + symptoms. Free T or calculated free T provides additional diagnostic clarity when SHBG is elevated.

📊

Normal Range

Total testosterone 300–1,000 ng/dL in adult men. Most TRT clinicians target 600–900 ng/dL for optimal symptom relief without excessive supraphysiological levels.

📉

Age-Related Decline

Testosterone declines approximately 1–2% per year after age 30. By age 70, most men have testosterone levels 35–50% below peak, though symptoms vary widely.

Formulations

Types of Testosterone

The ester attached to the testosterone molecule determines its half-life, injection frequency, and peak/trough profile. Choosing the right formulation is critical for stable levels and quality of life.

Most Common
💉

Testosterone Cypionate

Half-life: ~8 days | Oil-based injectable. The gold standard in the US. Administered IM or SubQ once or twice weekly. Stable levels, low cost, widely available. Typical dose: 100–200mg/week.

Popular in EU
💉

Testosterone Enanthate

Half-life: ~7 days | Nearly identical to cypionate. More common in Europe. Same dosing approach: 100–200mg/week IM or SubQ split 1–2x/week. Interchangeable for most protocols.

Shorter Ester
💉

Testosterone Propionate

Half-life: ~2 days | Requires every-other-day (EOD) or daily injection for stable levels. Faster-acting and quicker to clear. Used by some to minimize side effects. Water-based version (Aquatest) also available.

Topical
🧴

Testosterone Cream / Gel

Applied daily | Convenient but inconsistent absorption. DHT conversion is higher with scrotal application. Transfer risk to partners and children. Examples: AndroGel, Testim, compounded creams. 50–100mg/day typical.

Implant
⚙️

Testosterone Pellets

Half-life: 3–6 months | Subcutaneously implanted pellets (Testopel) release testosterone steadily. Inserted every 3–6 months. Convenient but cannot be adjusted after implant. Minor surgical procedure required.

Oral/Buccal
💊

Oral Testosterone (Jatenzo)

FDA approved 2019 | Testosterone undecanoate capsule taken with food twice daily. Avoids first-pass liver metabolism via lymphatic absorption. Elevated BP in some users. Less common due to cost.

💡
SubQ vs IM injections: Subcutaneous injection (belly fat, quads) is now preferred by many TRT clinicians over intramuscular (glutes, delts) due to equal efficacy, lower peak-to-trough variability, and easier self-administration. A 29-gauge ½" insulin syringe makes SubQ TRT straightforward.

Clinical Protocol

Typical TRT Protocol

A well-designed TRT protocol goes beyond testosterone alone. Managing co-medications and injection frequency is key to stable levels and minimizing side effects.

Component Drug / Compound Dose Range Frequency Purpose
Testosterone Cypionate or Enanthate 100–200mg 1–2x/week (SubQ preferred) Primary androgen replacement
Fertility Preservation HCG (Human Chorionic Gonadotropin) 250–500 IU 2–3x/week Maintain testicular function, preserve fertility, prevent atrophy
Aromatase Inhibitor Anastrozole or Exemestane 0.25–0.5mg 2x/week (if needed) Control estrogen elevation — only if E2 symptomatic + elevated
Donation / Hematocrit Therapeutic phlebotomy 1 unit blood As needed Manage hematocrit elevation (>52%)
⚠️
AI (aromatase inhibitors) should NOT be used prophylactically. Crashing estrogen causes joint pain, low libido, depression, and cardiovascular risk. Only use an AI when estradiol is symptomatic and confirmed elevated above 40–50 pg/mL (sensitive assay). Many men on TRT never need an AI.
✅
HCG co-administration preserves fertility. TRT alone suppresses the HPG axis, stopping LH/FSH secretion and halting sperm production. HCG mimics LH, stimulating the testes to maintain intratesticular testosterone and spermatogenesis. 250–500 IU 2–3x weekly is the standard adjunct protocol for men who want to preserve fertility options.

Protocol Startup: The Timeline

🩸

Baseline Bloodwork (Week 0)

Total T, free T, estradiol (sensitive), SHBG, LH, FSH, CBC, CMP, lipids, PSA. Two morning tests before starting. Fertility workup (semen analysis) if applicable.

💉

Initiation (Weeks 1–6)

Start testosterone at 100mg/week SubQ. Add HCG if desired. Adjust frequency and dosing. Note: testosterone levels require 4–6 weeks to stabilize. Do not judge efficacy too early.

📋

First Follow-Up Labs (Week 6)

Check total T, free T, estradiol, hematocrit. Assess symptom response. Adjust dose if trough levels are still low (<500 ng/dL). Draw labs at trough (just before next injection).

📊

3-Month Check (Week 12)

Full panel: T, free T, E2, CBC, lipids, PSA. Evaluate symptoms. Finalize protocol. Most patients achieve stable levels and symptom resolution by this point.

✅

Maintenance (Every 6 Months)

Ongoing monitoring every 6 months once stable. Annual PSA for men over 40. Donate blood if hematocrit creeps above 52%. Continue HCG if fertility is a priority.

Clinical Outcomes

What the Research Shows: TRT Results

Data from published clinical trials and meta-analyses examining TRT in hypogonadal men. Results represent average outcomes — individual response varies.

📚
Key source: The TRAVERSE Trial (2023, NEJM) — the largest RCT on TRT to date, with 5,246 men aged 45–80 with hypogonadism. Additional data from meta-analyses by Corona et al. (2016, European Journal of Endocrinology) covering 52 RCTs.

Testosterone Level Changes

Total Testosterone Restoration ~85%
Percentage of hypogonadal men reaching normal range (>400 ng/dL) on standard TRT protocols
Free Testosterone Normalization ~78%
Free T reaching normal range (>9 pg/mL) — more clinically relevant when SHBG is elevated

Symptom & Body Composition Improvements

Libido & Sexual Function Improvement ~70%
Corona et al. meta-analysis: significant improvement in sexual desire, frequency, and satisfaction vs. placebo
Mood & Energy Improvement ~65%
Reported improvements in energy levels, fatigue reduction, and depressive symptom reduction in hypogonadal men
Lean Muscle Mass Increase ~60%
Average gain of 1.5–3 kg lean mass over 12 months in multiple RCTs; response enhanced with resistance training
Fat Mass Reduction ~55%
Average reduction of 1–2 kg total fat mass; more pronounced with combined TRT + exercise intervention
Bone Mineral Density Improvement ~50%
Lumbar spine BMD significantly increased vs. placebo in studies of 12+ months — relevant for long-term osteoporosis prevention
📋
TRAVERSE Trial Key Finding (2023): TRT did not increase major adverse cardiovascular events (MACE) vs. placebo in hypogonadal men with cardiovascular risk. However, it was associated with a slightly higher rate of atrial fibrillation and pulmonary embolism — underscoring the importance of monitoring.

Safety Profile

Side Effects & How to Manage Them

TRT has a well-characterized safety profile. Most side effects are dose-dependent and manageable with proper monitoring. Incidence data from pooled clinical trials.

Hematocrit Elevation (>52%) ~15–20%
Management: Regular CBC monitoring. Donate blood (therapeutic phlebotomy) every 2–4 months if needed. Stay hydrated. Reduce dose. Most common side effect requiring intervention.
Estrogen Elevation (E2 >40 pg/mL) ~10–15%
Management: Symptoms include water retention, gynecomastia, mood swings. Confirm with sensitive estradiol test. Low-dose anastrozole (0.25–0.5mg 2x/week) if symptomatic. Many men do well with elevated E2 if asymptomatic.
Acne / Oily Skin ~10%
Management: Often resolves in first 3–6 months. Benzoyl peroxide wash, vitamin C serum, or topical retinoids if persistent. Reduce dose if severe. More common in men with prior acne history.
Testicular Atrophy ~20–40% without HCG
Management: Largely preventable with HCG co-administration (250–500 IU 2–3x/week). HCG maintains intratesticular testosterone and testicular volume. Mostly cosmetic, but important for fertility preservation.
Hair Loss Acceleration (DHT-Sensitive Men) ~5–15%
Management: Only relevant in men genetically predisposed to androgenic alopecia. TRT doesn't cause hair loss but can accelerate it. Topical minoxidil, finasteride (1mg/day), or microneedling can mitigate progression.
Sleep Apnea Worsening ~5%
Management: TRT can worsen obstructive sleep apnea. Screen patients at baseline. Use CPAP if diagnosed. Reduced with lower doses. Important to address as sleep apnea independently suppresses testosterone.
🚫
Contraindications: TRT is contraindicated in men with: active prostate or breast cancer, recent major cardiovascular event (within 3–6 months), severe BPH with urinary obstruction, hematocrit >54%, or desire for fertility without HCG co-administration. Always disclose full medical history to your prescribing physician.

Lab Monitoring

Bloodwork: What to Test & When

Consistent lab monitoring is non-negotiable on TRT. These are the key markers to track and what optimal ranges look like.

Total Testosterone
Primary marker. Draw at trough (just before next injection) for accurate baseline comparison.
Target: 500–900 ng/dL (trough)
Free Testosterone
Bioavailable T. Critical when SHBG is high. Use calculated free T or equilibrium dialysis method.
Target: 15–25 pg/mL
Estradiol (Sensitive)
Must use the "sensitive" or "LC-MS/MS" assay — not the standard immunoassay, which is inaccurate for men.
Target: 20–40 pg/mL
Hematocrit / CBC
TRT stimulates red blood cell production. Elevated hematocrit increases clot risk. Most important safety marker.
Target: <52%
SHBG
Sex hormone binding globulin determines free T. High SHBG lowers free T; low SHBG raises it. Guides dosing decisions.
Target: 18–54 nmol/L
PSA
Prostate-specific antigen. Baseline + annual monitoring for men over 40. TRT may unmask subclinical prostate disease.
Target: <4 ng/mL; no rapid rise
Lipid Panel
TRT can lower HDL and raise LDL (especially with injectables). Annual monitoring; address with diet, exercise, or statins if needed.
HDL >40, LDL <130 mg/dL
LH / FSH (Baseline)
Distinguish primary (testicular) vs. secondary (pituitary) hypogonadism. LH/FSH will be suppressed on TRT — only useful at baseline.
Diagnostic — baseline only

Monitoring Schedule

Time Point Labs Required Key Decisions
Baseline (Before TRT) Full panel: T, free T, E2, SHBG, LH, FSH, CBC, CMP, lipids, PSA Confirm diagnosis; rule out contraindications
6 Weeks Total T (trough), free T, E2 (sensitive), hematocrit Dose adjustment; assess E2 and hematocrit
3 Months Full panel (skip LH/FSH): T, free T, E2, CBC, lipids, PSA Finalize protocol; long-term safety check
Every 6 Months T, free T, E2, CBC, lipids Ongoing safety monitoring; donate blood if Hct high
Annually (40+) Full panel including PSA, digital rectal exam Prostate health; cardiovascular risk review

Comparative Options

TRT vs. Natural Alternatives

TRT is not the only option for men with low testosterone. Here's how it compares to alternatives that preserve the HPG axis.

Approach T Increase HPG Axis Fertility Best For
TRT (Testosterone Cypionate) +++  (300→800+ ng/dL) Suppressed Preserved with HCG Confirmed hypogonadism, symptom relief priority
Enclomiphene ++  (~175% increase) Intact (stimulated) Maintained Younger men, fertility preservation, secondary hypogonadism
HCG Monotherapy ++  (moderate) Intact (LH mimicry) Maintained Men wanting testicular stimulation without T shutdown
Lifestyle Optimization +  (10–15%) Intact Maintained Borderline T, addressing root causes (sleep, obesity, stress)
Clomiphene (Clomid) ++  (moderate) Intact (stimulated) Maintained Fertility-focused; note: contains zuclomiphene (estrogenic isomer)
💡
Lifestyle first for borderline cases. Before TRT, address: sleep (7–9 hours), obesity (weight loss raises T ~30% at BMI reduction of 5 units), strength training, stress (cortisol suppresses T), and vitamin D/zinc/magnesium deficiency. Many men in the 300–400 ng/dL range can optimize to symptom-free levels without TRT.
💊

Enclomiphene Guide →

The trans-isomer of clomiphene that raises testosterone ~175% while preserving the HPG axis and fertility. Ideal for secondary hypogonadism and younger men.
🧬

HCG Guide →

Complete guide to HCG for TRT adjunct and monotherapy. Protocols, dosing, fertility impact, and how FDA compounding changes affect access.

Summary

Key Takeaways

✅ What We Know

  • TRT reliably restores testosterone to physiological ranges in hypogonadal men
  • Libido, energy, mood, and body composition improve significantly vs. placebo in confirmed hypogonadism
  • HCG co-administration preserves testicular function and fertility during TRT
  • SubQ injection frequency (1–2x/week) produces stable T levels equivalent to IM
  • TRAVERSE Trial (2023): TRT does not increase major cardiovascular events in hypogonadal men
  • Hematocrit elevation is manageable with regular monitoring and therapeutic phlebotomy
  • Bone mineral density and lean mass improve significantly over 12+ months
  • AI (aromatase inhibitors) are only needed if estradiol is symptomatic and elevated

⚠️ What We Don't Know

  • Long-term cardiovascular outcomes (20+ years) — most trials are 1–3 years
  • Optimal target T range — whether 700 ng/dL is significantly better than 500 ng/dL for symptoms
  • Whether TRT reverses the causes of hypogonadism or simply manages symptoms
  • Long-term prostate safety — evidence suggests no increase in prostate cancer, but very long-term data limited
  • Full impact on cognitive function — some studies show modest improvement, others show no effect
  • Whether TRT-induced erythrocytosis truly increases VTE risk to the same degree as other causes
  • Optimal duration of therapy — lifetime treatment vs. intermittent cycles not well studied

🛒 Recommended Products for TRT

Practical supplies for self-administered TRT protocols and supporting supplementation.

💉 Insulin Syringes 29g ½" 29-gauge, ½" insulin syringes — ideal for SubQ testosterone injections. Low-dead-space tip recommended. 🧼 Sterile Alcohol Swabs 70% isopropyl alcohol prep pads for vial tops and injection sites. Box of 200. 🗑️ Sharps Container FDA-compliant needle disposal container for safe sharps disposal at home. 🔬 DHEA Supplement 25–50mg DHEA to support adrenal hormone levels and upstream T precursor pathway. ☀️ Vitamin D3 + K2 5,000 IU D3 + 100mcg K2 (MK-7). Vitamin D deficiency suppresses testosterone and is extremely common. ⚡ Zinc + Magnesium (ZMA) Zinc and magnesium deficiencies both independently lower testosterone. ZMA formulations combine both.

Affiliate links help support MeetPeptide at no extra cost to you.

📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.


Get the Guide →
Disclaimer: This page is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Testosterone replacement therapy is a prescription medication — it must be prescribed and monitored by a licensed healthcare provider. Data presented is sourced from published peer-reviewed research; individual results will vary. Always consult with a qualified physician, endocrinologist, or urologist before starting, stopping, or adjusting any hormone therapy. The TRAVERSE Trial and other citations referenced on this page are summarized for educational purposes — read original sources for full context.